false
0002022416
00-0000000
0002022416
2026-11-19
2026-11-19
0002022416
us-gaap:CommonStockMember
2026-11-19
2026-11-19
0002022416
SLXN:WarrantsExercisableForOrdinarySharesMember
2026-11-19
2026-11-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
November 19, 2026 (November 18, 2026)
Silexion Therapeutics
Corp
(Exact name of registrant as specified in its charter)
| Cayman Islands |
|
001-42253 |
|
N/A |
| (State or other jurisdiction |
|
(Commission File Number) |
|
(I.R.S. Employer |
| of incorporation) |
|
|
|
Identification No.) |
|
12 Abba Hillel Road
Ramat-Gan, Israel |
|
5250606 |
| (Address of principal executive offices) |
|
(Zip Code) |
+972-3-7564999
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on
which registered |
| Ordinary Shares, par value $3.24 per share |
|
SLXN |
|
The Nasdaq Stock Market LLC |
| Warrants exercisable for Ordinary Shares at an exercise price of $372,600.00 per share |
|
SLXNW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
Outcome of Nasdaq Hearings Panel; Continued Listing
On November 18, 2026, Silexion Therapeutics Corp.
(the “Company”) received a favorable decision from a Nasdaq Hearings Panel granting the Company’s request for
continued listing on the Nasdaq Capital Market, subject to the conditions described below. The decision followed the Company’s appeal
of Nasdaq’s August 18, 2026 delisting determination relating to the Company’s non-compliance with the $2.5 million minimum
shareholders’ equity requirement and also addressed the Company’s non-compliance with Nasdaq’s $1.00 minimum bid price
requirement.
In its final form, the Panel’s decision
requires the Company to: (i) by December 4, 2026, complete its planned private placement financing for net proceeds of $2.5 million and
demonstrate compliance with, and its ability to maintain compliance with, the minimum shareholders’ equity requirement, including
through a balance sheet dated no more than 60 days prior to the applicable SEC filing; (ii) by November 24, 2026, demonstrate compliance
with the minimum bid price requirement by maintaining a closing bid price of at least $1.00 per share for at least ten consecutive trading
days; and (iii) by March 31, 2027, complete a planned public offering of at least $5 million.
The Company is also required to maintain compliance
with all Nasdaq listing requirements through May 15, 2027. Failure to comply with any Nasdaq listing requirement during this period, other
than the existing deficiencies being addressed pursuant to the foregoing conditions, will result in immediate delisting.
As previously reported, in furtherance of its efforts to regain compliance
with the minimum bid price requirement, the Company effected a 1-for-24 reverse share split on November 10, 2026, which became effective
for trading purposes on November 11, 2026.
There can be no assurance that the Company will
satisfy the conditions imposed by the Panel or otherwise regain or maintain compliance with the applicable Nasdaq continued listing requirements.
Forward-Looking Statements
This Current Report on Form 8-K contains certain
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Some of the forward-looking statements
can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “anticipate,”
“expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,”
“targets,” “projects,” “should,” “could,” “would,” “may,” “will,”
“forecast” and other similar expressions are intended to identify forward-looking statements. Those statements include, without
limitation, those related to: the Company’s ability to complete its planned private placement financing and restore compliance with
the minimum shareholders’ equity requirement by the December 4, 2026 deadline; the Company’s ability to demonstrate compliance
with the minimum bid price requirement by November 24, 2026; the Company’s ability to complete its planned public offering of at
least $5.0 million by March 31, 2027; the Company’s ability to maintain compliance with all Nasdaq listing rules through May 15,
2027; and all other statements that are not historical facts. Forward-looking statements are predictions, projections and other statements
about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many
factors could cause actual future events to differ materially from the forward-looking statements in this Current Report on Form 8-K,
including, but not limited to, that: the Company may not be successful in completing the steps required of it to maintain its Nasdaq listing
in the timeframe required by the Panel’s decision; and the Company may encounter other difficulties in maintaining compliance with
all Nasdaq listing standards through May 15, 2027, which would result in the immediate delisting of its securities. The foregoing list
of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the
“Risk Factors” section of the Company’s filings with the SEC, including the Company’s Annual Report on
Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s Quarterly Report on Form
10-Q for the quarter ended September 30, 2026, filed with the SEC on November 12, 2026. Those filings identify and address other important
risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking
statements, and the Company assumes no obligation and does not intend to update or revise those forward-looking statements, whether as
a result of new information, future events, or otherwise. The Company does not give any assurance that it will achieve its expectations.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
SILEXION THERAPEUTICS CORP |
| |
|
| Date: November 19, 2026 |
/s/ Ilan Hadar |
| |
Name: |
Ilan Hadar |
| |
Title: |
Chief Executive Officer |